Short Interest in Cocrystal Pharma, Inc. (NASDAQ:COCP) Decreases By 18.8%

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the recipient of a significant decline in short interest during the month of March. As of March 13th, there was short interest totaling 214,196 shares, a decline of 18.8% from the February 26th total of 263,840 shares. Approximately 2.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 34,698 shares, the days-to-cover ratio is presently 6.2 days.

Cocrystal Pharma Price Performance

NASDAQ COCP traded up $0.03 on Tuesday, hitting $1.03. 20,507 shares of the company were exchanged, compared to its average volume of 62,838. The company’s 50 day moving average price is $1.02 and its 200-day moving average price is $1.07. The firm has a market capitalization of $14.12 million, a P/E ratio of -1.09 and a beta of 1.18. Cocrystal Pharma has a twelve month low of $0.86 and a twelve month high of $2.67.

Cocrystal Pharma (NASDAQ:COCP) last announced its earnings results on Tuesday, March 31st. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.01. As a group, equities analysts expect that Cocrystal Pharma will post -1.85 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cocrystal Pharma in a research note on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $6.00.

Insider Transactions at Cocrystal Pharma

In related news, Director Phillip Md Et Al Frost purchased 50,000 shares of the company’s stock in a transaction on Friday, February 6th. The shares were bought at an average price of $0.95 per share, with a total value of $47,500.00. Following the completion of the acquisition, the director owned 1,888,551 shares of the company’s stock, valued at approximately $1,794,123.45. This represents a 2.72% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 28.14% of the company’s stock.

Hedge Funds Weigh In On Cocrystal Pharma

An institutional investor recently bought a new position in Cocrystal Pharma stock. DRW Securities LLC acquired a new position in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned approximately 0.24% of Cocrystal Pharma as of its most recent filing with the Securities and Exchange Commission. 6.72% of the stock is owned by institutional investors.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.